July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Anterior flare intensity after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema
Author Affiliations & Notes
  • masakazu morioka
    University of Fukui Hospital, Yoshida, Fukui, Japan
  • Yoshihiro Takamura
    University of Fukui Hospital, Yoshida, Fukui, Japan
  • Yutaka Yamada
    University of Fukui Hospital, Yoshida, Fukui, Japan
  • makoto gozawa
    University of Fukui Hospital, Yoshida, Fukui, Japan
  • takehiro matsumura
    University of Fukui Hospital, Yoshida, Fukui, Japan
  • Masaru Inatani
    University of Fukui Hospital, Yoshida, Fukui, Japan
  • Footnotes
    Commercial Relationships   masakazu morioka, None; Yoshihiro Takamura, None; Yutaka Yamada, None; makoto gozawa, None; takehiro matsumura, None; Masaru Inatani, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4851. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      masakazu morioka, Yoshihiro Takamura, Yutaka Yamada, makoto gozawa, takehiro matsumura, Masaru Inatani; Anterior flare intensity after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4851.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate anterior flare intensity (AFI) after intravitreal injection of aflibercept (IVA), ranibizumab (IVR) or triamcinolone acetonide (IVTA) in patients with diabetic macular edema (DME).

Methods : This study was conducted as a prospective study for the patients with DME. The patients with phakic eyes were received either IVA or IVR, and the patients with pseudophakic eyes were received 1:1:1 either IVA, IVR or IVTA. AFI and central retinal thickness (CRT) were measured with the laser flare meter and spectral domain optical coherence tomography, respectively, at days 0, 1, 7, 30 and 90.

Results : Forty patients with phakic eyes and 60 patients with pseudophakic eyes were enrolled. In the IVTA group, AFI of pseudophakic eyes was decreased significantly at days 1 (p = 0.0487), 7 (p = 0.0201), and 30 (p = 0.0211). In the IVA groups, AFI of phakic eyes was transiently increased at day 1 (p = 0.0078) and then returned to baseline level at day 7, while no significant change was found in AFI of pseudophakic eyes. In the IVR group, there was no significant change in AFI regardless of phakic condition. All groups showed the significant reduction of CRT at days 7 and thereafter.

Conclusions : DME was successfully improved after the treatment of IVTA, IVR or IVA, while the reduction of AFI was noticed in the eyes treated with IVTA only. The temporal profiles of AFI is probably reflected by the difference of the pharmacological property among the drugs.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×